

09/ 924,381

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Jan 25 BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3 Jan 29 FSTA has been reloaded and moves to weekly updates
NEWS 4 Feb 01 DKILIT now produced by FIZ Karlsruhe and has a new update
frequency
NEWS 5 Feb 19 Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6 Mar 08 Gene Names now available in BIOSIS
NEWS 7 Mar 22 TOXLIT no longer available
NEWS 8 Mar 22 TRCTHERMO no longer available
NEWS 9 Mar 28 US Provisional Priorities searched with P in CA/Caplus
and USPATFULL
NEWS 10 Mar 28 LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11 Apr 02 PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12 Apr 08 "Ask CAS" for self-help around the clock
NEWS 13 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14 Apr 09 ZDB will be removed from STN
NEWS 15 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 16 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 18 Apr 22 Federal Research in Progress (FEDRIP) now available

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:58:38 ON 02 MAY 2002

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

09/ 924,381

FILE 'REGISTRY' ENTERED AT 12:58:42 ON 02 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 30 APR 2002 HIGHEST RN 409303-45-3
DICTIONARY FILE UPDATES: 30 APR 2002 HIGHEST RN 409303-45-3

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STN Note 27, Searching Properties in the CAS
Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s pyrazol? or triazol? or tetrazol? or isoxazol?

445489 PYRAZOL?

314860 TRIAZOL?

94975 TETRAZOL?

124067 ISOXAZOL?

L1 949882 PYRAZOL? OR TRIAZOL? OR TETRAZOL? OR ISOXAZOL?

=> s (sulphonyl or sulfonyl) and biphenyl

90 SULPHONYL

717985 SULFONYL

278269 BIPHENYL

L2 17350 (SULPHONYL OR SULFONYL) AND BIPHENYL

=> s l1 and l2

L3 2804 L1 AND L2

=> s (isoquinolin? or benzisoxazol? or indazol? or quinolin? or quinazol?)

188765 ISOQUINOLIN?

14129 BENZISOXAZOL?

37218 INDAZOL?

406345 QUINOLIN?

180878 QUINAZOL?

L4 822183 (ISOQUINOLIN? OR BENZISOXAZOL? OR INDAZOL? OR QUINOLIN? OR QUINAZOL?)

=> s l1 and l2 and l3

L5 2804 L1 AND L2 AND L3

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

51.04

51.25

FILE 'CAPLUS' ENTERED AT 13:03:38 ON 02 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.

09/ 924,381

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 May 2002 VOL 136 ISS 18
FILE LAST UPDATED: 30 Apr 2002 (20020430/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l5

L6 299 L5

=> s l6 and thromboembol?

3071 THROMBOEMBOL?

L7 12 L6 AND THROMBOEMBOL?

=> d l7 1- ibib abs

YOU HAVE REQUESTED DATA FROM 12 ANSWERS - CONTINUE? Y/(N):y

L7 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:39605 CAPLUS

DOCUMENT NUMBER: 136:102380

TITLE: Preparation of novel guanidine mimics as factor Xa inhibitors

INVENTOR(S): Lam, Patrick Y.; Clark, Charles G.; Dominguez, Celia; Fevig, John M.; Han, Qi; Li, Renhua; Pinto, Donald J. P.; Pruitt, James R.; Quan, Mimi L.

PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA

SOURCE: U.S., 117 pp.

CODEN: USXXAM



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6339099	B1	20020115	US 1998-99358	19980618
US 2002025963	A1	20020228	US 2001-924381	20010808
PRIORITY APPLN. INFO.:			US 1997-50265P	P 19970620
			US 1998-99358	A3 19980618
OTHER SOURCE(S):		MARPAT 136:102380		
GI				



AB The title compds. [I; ring D = 5-membered arom. system contg. from 1-2 heteroatoms selected from N, O, S; ring D is substituted with 0-2 R groups; ring E contains 0-2 N atom and is substituted by 0-1 R groups; R = Cl, F, Br, I, OH, alkoxy, amino(alkyl), (alkyl)amino; Z = bond, alkylene, (CH₂)_rO(CH₂)_r, (CH₂)_rNR₃(CH₂)_r, (CH₂)_rC(O)(CH₂)_r, (CH₂)_rC(O)O(CH₂)_r, (CH₂)_rOC(O)(CH₂)_r, (CH₂)_rC(O)NR₃(CH₂)_r, etc. provided that Z does not form a N-N, N-O, N-S, NCH₂N, NCH₂O, or NCH₂S bond with ring M or group A; R_{1a}-1b = H, alk(en)yl, aminoalkyl, alkoxy, alternatively, R_{1a}-1b, when attached to adjacent carbon atoms, together with the atoms to which they are attached form a 5-8 membered (un)satd. ring (un)substituted and which contains from 0-2 heteroatoms selected from the group consisting of N, O, and S; alternatively, when Z is C(O)NH and R_{1a} is attached to a ring carbon adjacent to Z, then R_{1a} is a C(O) which replaces the amide hydrogen of Z to form a cyclic imide; R₃ = H, alkyl, phenyl; A = (un)substituted carbocyclic, 5-10 membered heterocyclic system contg. 1-4 heteroatoms selected from N, O, S; B = H, Y, X-Y; X = sulfonylalkyl, alkylsulfonyl, sulfonamide, etc.; Y = alkylamino, provided that X-Y does not form a N-N, O-N or S-N bond, carbocyclic group, 5-10 membered heterocyclic r = 0-3], inhibitors of factor Xa which are useful in treating and preventing a **thromboembolic** disorder, were prepd. and formulated. Thus, a multi-step synthesis of the title compd. II, starting with 7-aminoisoquinoline, was described. A no. of compds. I were found to exhibit a K_i of .ltoreq. 15 .mu.M against factor Xa.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:10474 CAPLUS

DOCUMENT NUMBER: 136:69811

TITLE: Preparation of 1-(heteroarylphenyl) condensed pyrazole derivatives as factor Xa inhibitors for treatment of **thromboembolic** disorders

INVENTOR(S): Pinto, Donald J. P.; Quan, Mimi L.; Woerner, Francis J.; Li, Renhua

PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA

SOURCE: PCT Int. Appl., 267 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000655	A1	20020103	WO 2001-US20113	20010622
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			





PRIORITY APPLN. INFO.:

US 2000-214032P P 20000623

OTHER SOURCE(S):

MARPAT 136:69811

GI



AB Title compds. I, II, and III [wherein ring D1 = pyridine, pyrazine, pyridazine, or pyrimidine substituted with 1 Ra and 0-1 Rb; ring D2 and ring D3 = 5-membered heteroarom. ring substituted with 1 Ra and 0-1 Rb; E = O, S, or NRc; R, Ra, and Rb = independently H, alkyl, halo, OH, alkoxy, CN, (un)substituted carboximidamido, , guanidino, or amino(alkyl), OCF₃, etc.; Rc = H, alkyl, alkoxy, (un)substituted carboximidamido, , guanidino, or amino(alkyl), OCF₃, etc.; G = absent or (CH₂)₁₋₃, (CH₂)₀₋₂CO(CH₂)₀₋₂, (CH₂)₀₋₂NR₃(CH₂)₀₋₂, or (CH₂)₀₋₂SOp(CH₂)₀₋₂; G1 = absent or (un)substituted alkyl, alkenyl, alkynyl, (CH₂)uCO(CH₂)w, (CH₂)uCO₂(CH₂)w, (CH₂)uOCO(CH₂)w, (CH₂)uO(CH₂)w, or (CH₂)uNR₃(CH₂)w, etc.; G2 = Ph, naphthyl, or a 5-10 membered heteroaryl ring; R₃ = independently H, alkyl, or Ph; p = 0-2; u + w = 0-4; Q = substituted pyrazolo[4,3-d]pyrimidinone, pyrazolo[4,3-d]pyridazinone, pyrazolo[3,4-c]pyridinone, etc.; and pharmaceutically acceptable salts thereof] were prep'd. as inhibitors of factor Xa. For example, 1-[4-bromophenyl]-4-acetyl-2,3-dioxopiperidine was prep'd. in four steps in 10% overall yield starting from 4-bromoaniline and 5-chloro-2-pentanone ethylene ketal. Addn. of 3-cyanophenyl hydrazine in glacial AcOH, followed by coupling with 2-(tert-butylaminosulfonyl)phenylboronic acid, afforded the biphenyl intermediate (no data). Treatment of the nitrile with thiosemicarbazide gave the aminothiadiazole IV. Some of the invention compds. inhibited factor Xa with K_i values of .ltoreq. 10 .mu.M. Thus, I, II, and III are useful as anticoagulants for the treatment or prevention of **thromboembolic**

disorders (no data).

REFERENCE COUNT: 7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:10470 CAPLUS

DOCUMENT NUMBER: 136:85810

TITLE: Preparation of arylamides and heterocyclamides as
factor Xa inhibitors for treatment of
thromboembolic disordersINVENTOR(S): Quan, Mimi L.; Lam, Patrick Y.; Li, Yunlong; Pinto,
Donald J. P.

PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA

SOURCE: PCT Int. Appl., 192 pp.

CODEN: PIXXD2




DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000651	A2	20020103	WO 2001-US20538	20010627
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2000-214758P	P 20000627
			US 2000-246124P	P 20001106
OTHER SOURCE(S):			MARPAT 136:85810	
GI				



AB Title compds. I and II [wherein ring M, including M1, M2, and, if present, M3 = 5-membered arom. heterocycle substituted with 0-2 R1a; or ring M = isoxazoline, isothiazoline, pyrazoline, triazoline, or tetrazoline substituted with 0-2 R1a; R1a = H, (un)substituted alkyl, alkenyl, amino, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amido, alkoxycarbonylamino, aminocarboxy, etc.; G = 5-6 membered (hetero)cycle optionally fused to Ph, pyridyl, pyrimidyl, pyrazinyl, or pyridazinyl substituted with 0-2 R; R = H, alkyl, halo, OH, alkoxy, CN, (un)substituted carboximidamido, (alkyl)amino, OCF₃, etc.; Z = a bond, (un)substituted (CH₂)₁₋₄, (CH₂)pO(CH₂)_q, (CH₂)pCO(CH₂)_q, (CH₂)pOCO(CH₂)_q, (CH₂)pCO₂(CH₂)_q, (CH₂)pNH(CH₂)_q, etc.; p + q = 0-2; Z1 = (un)substituted (CH₂)₁₋₅, (CH₂)₀₋₂CH=CH(CH₂)₀₋₂, (CH₂)₀₋₂C.tplbond.C(CH₂)₀₋₂, (CH₂)uCO(CH₂)_w, (CH₂)uCO₂(CH₂)_w, (CH₂)uO(CH₂)_w, (CH₂)uNH(CH₂)_w, etc.; u + w = 0-4; A = (un)substituted carbocycle or heterocycle; B = H, Y, or XY; X = (un)substituted (CH₂)₁₋₄, CO, C(NH), CH(NH₂), CH(OH), CH(SH), COCH₂, CH₂CO, S, SO, SO₂, NHCO, CONH, O, etc.; Y = (un)substituted carbocycle or heterocycle] were prepd. as inhibitors of trypsin-like serine protease enzymes, esp. factor Xa. For example, 4-biphenylcarboxaldehyde oxime (prepn. given) was treated with itaconic acid monomethyl ester and bleach in THF to give 3-([1,1']-biphen-4-yl)-5-(carbomethoxymethyl)isoxazolin-5-ylcarboxylic acid (84%). Amidation with 3-cyanoaniline (28%), followed by conversion to the amidine and elution with TFA, afforded III.bul.TFA. Some of the invention compds. inhibited factor Xa with K_i values of .ltoreq. 10 .mu.M. Thus, I and II are useful as anticoagulant agents for treatment and prevention of **thromboembolic** disorders.

L7 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:10466 CAPLUS

DOCUMENT NUMBER: 136:85809

TITLE: Preparation of heteroarylphenyl substituted factor Xa inhibitors for treatment of **thromboembolic** disorders

INVENTOR(S): Pinto, Donald J. P.; Quan, Mimi L.; Woerner, Francis J.

PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA

SOURCE: PCT Int. Appl., 146 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000647	A1	20020103	WO 2001-US20112	20010622
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2000-214033P P 20000623

OTHER SOURCE(S): MARPAT 136:85809

GI



AB Title compds. I, II, and III [wherein ring D1 = pyridine, pyrazine, pyridazine, or pyrimidine substituted with 1 Ra and 0-1 Rb; ring D2 = 5-membered heteroarom. ring substituted with 1 Ra and 0-1 Rb; E = O, 3S, or NRc; ring D3 = 5-membered heteroarom. ring substituted with 1 Ra and 0-1 Rb; R, Ra, and Rb = H, alkyl, halo, OH, alkoxy, CN, (un)substituted carboximidamido, (alkyl)amino, OCF₃, etc.; Rc = H, alkyl, alkoxy, (un)substituted (alkyl)amino, OCF₃, etc.; G = absent or (CH₂)₁₋₃, (CH₂)₀₋₂CO(CH₂)₀₋₂, (CH₂)₀₋₂O(CH₂)₀₋₂, (CH₂)₀₋₂NH(CH₂)₀₋₂, (CH₂)₀₋₂Sop(CH₂)₀₋₂, etc.; p = 0-2; G1 = (un)substituted (CH₂)₁₋₅, (CH₂)₀₋₂CH=CH(CH₂)₀₋₂, (CH₂)₀₋₂C.tplbond.C(CH₂)₀₋₂, (CH₂)uCO(CH₂)w, (CH₂)uOCO(CH₂)w, (CH₂)uCO₂(CH₂)w, (CH₂)uNH(CH₂)w, etc.; u + w = 0-4; G2 = Ph, naphthyl, or heteroaryl; M = isoxazoline, pyrazoline, isothiazoline, triazoline tetrazoline, Ph, or substituted 5-6 membered heteroaryl; and pharmaceutically acceptable salts or prodrugs thereof] were prep'd. as factor Xa inhibitors. For example, HCl gas was bubbled through 1-(3-cyanophenyl)-3-trifluoromethyl-5-[(2'-sulfonylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole in anhyd. EtOH to afford the ethoxyimide intermediate. Addn. of N-methylmorpholine to the crude product in dioxane, followed by cyclization with semicarbazide.bul.HCl, gave the pyrazolamide IV. Some of the invention compds. inhibited factor Xa with Ki values of .ltoreq. 10 .mu.M. Thus, I are useful as anticoagulants for the treatment of **thromboembolic** disorders (no data).

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2002 ACS


ACCESSION NUMBER: 2001:338499 CAPLUS
DOCUMENT NUMBER: 134:348280
TITLE: Cyano compounds as factor Xa inhibitors
INVENTOR(S): Pinto, Donald J. P.
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032628	A1	20010510	WO 2000-US30209	20001102
W: US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,				


PT, SE, TR
 PRIORITY APPLN. INFO.:
 OTHER SOURCE(S):
 GI

US 1999-163268P P 19991103


MARPAT 134:348280




Ia



Ib



Ic



Id

AB The present application describes inhibitors of factor Xa which are cyano-pyrazole, cyano-triazole, cyano-imidazole, and cyano-pyrrole compds. of Formulas Ia, Ib, Ic, and Id: or pharmaceutically acceptable salt forms thereof. Markush structures and exemplary compds. of the invention are given (no data).

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:83115 CAPLUS

DOCUMENT NUMBER: 132:137392

TITLE: Preparation of azoles as Factor Xa inhibitors.

INVENTOR(S): Pinto, Donald Joseph Phillip; Pruitt, James Russell; Cacciola, Joseph; Fevig, John Matthew; Han, Qi; Orwat, Michael James; Quan, Mimi Lifan; Rossi, Karen Anita

PATENT ASSIGNEE(S): Dupont Pharmaceuticals Co., USA

SOURCE: U.S., 152 pp.

CODEN: USXXAM


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6020357	A	20000201	US 1997-995834	19971222
PRIORITY APPLN. INFO.:			US 1996-33437P	P 19961223
			US 1997-50304P	P 19970620
OTHER SOURCE(S):		MARPAT 132:137392		
GI				



AB Title compds. [I; ring M contains, in addn. to J, 0-3 N atoms; J = N, NH; D = CN, C(:NR₈)NR₇R₉, C(O)NR₇R₈, etc.; E = (un)substituted Ph, pyridyl, pyrimidinyl, etc.; DEG = R-substituted pyridyl; R = H, halo, CF₃, etc.; G = absent, NHCH₂, OCH₂, etc.; Z = C1-4 alkylene, (CH₂)_rO(CH₂)_r, etc.; R_{1a}, R_{1b} = absent, NMe, OMe, etc.; A = (un)substituted C3-10 carbocyclic residue, 5-10 membered heterocyclic contg. from 1-4 heteroatoms selected from N, O, and S; B = (un)substituted C3-10 carbocyclic residue, 5-10 membered heterocyclic contg. from 1-4 heteroatoms selected from N, O, and S, etc.; R₇ = H, OH, C1-6 alkyl, etc.; R₈, R₉ = H, C1-6 alkyl, (CH₂)_nPh; n = 0-3; r = 0-3; s = 0-2; with provisos], useful as inhibitors of factor Xa, were prepd. and formulated. Thus, treatment of 4-[o-(tert-BuSO₂)phenyl]aniline with Me₃Al/hexane in CH₂Cl₂ followed by the addn. of Me 1-(3-cyanophenyl)imidazol-2-ylcarboxylate (prepn. described), and the Pinner reaction of the resulting intermediate afforded 1-(3-amidinophenyl)-2-[(2'-aminosulfonyl-1,1'-biphen-4-yl)aminocarbonyl]imidazole. Several I showed K_i .ltoreq.10 .mu.M against Factor Xa and thrombin.

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:9833 CAPLUS
DOCUMENT NUMBER: 130:66494
TITLE: Preparation of novel guanidine mimics as factor Xa inhibitors
INVENTOR(S): Lam, Patrick Y.; Clark, Charles G.; Dominguez, Celia; Fevig, John Matthew; Han, Qi; Li, Renhua; Pinto, Donald Joseph-Phillip; Pruitt, James Russell; Quan, Mimi Lifan
PATENT ASSIGNEE(S): The Du Pont Merck Pharmaceutical Company, USA
SOURCE: PCT Int. Appl., 268 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9857951	A1	19981223	WO 1998-US12680	19980618
W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9879768	A1	19990104	AU 1998-79768	19980618
EP 991638	A1	20000412	EP 1998-930361	19980618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9810137	A	20000808	BR 1998-10137	19980618
JP 2002505686	T2	20020219	JP 1999-504785	19980618
NO 9905965	A	19991203	NO 1999-5965	19991203
LV 12496	B	20010120	LV 1999-178	19991216
LT 4705	B	20000925	LT 1999-147	19991217
PRIORITY APPLN. INFO.:			US 1997-878884	A 19970619

OTHER SOURCE(S) :
GI

MARPAT 130:66494



II

AB The title compds. [I; rings D-E represent guanidine mimics; ring D = CH₂N:CH, CH₂CH₂N:CH, a 5-6 membered arom. system contg. 0-2 heteroatoms selected from the group N, O, and S; ring D is substituted with 0-2 R (substituents), provided that when ring D is unsubstituted, it contains at least one heteroatom; ring E contains 0-2 N atom and is substituted by 0-1 R; R = halo, OH, C1-3 alkoxy, etc.; M = (un)substituted pyrazole, imidazole, tetrazole, etc.], inhibitors of factor Xa which are useful in treating and preventing a **thromboembolic** disorder, were prep'd. and formulated. Thus, a multi-step synthesis of the title compd. II, starting with 7-aminoisoquinoline, was described. A no. of compds. I were found to exhibit a K_i of .ltoreq. 15 .mu.M against factor Xa.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:816104 CAPLUS

DOCUMENT NUMBER: 130:66484

TITLE: Preparation of isoxazoline and isoxazole fibrinogen receptor antagonists

INVENTOR(S): Wityak, John; Xue, Chu-Biao; Sielecki-Dzurdz, Thais Motria; Olson, Richard Eric; Degrado, William Frank; Cain, Gary Avonn; Batt, Douglas Guy; Pinto, Donald; Hussain, Munir Alwan; Mousa, Shaker Ahmed

PATENT ASSIGNEE(S): The DuPont Merck Pharmaceutical Company, USA

SOURCE: U.S., 153 pp., Cont.-in-part of U.S. Ser. No. 337,920, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5849736	A	19981215	US 1995-455436	19950531
CA 2174838	AA	19950601	CA 1994-2174838	19941114
HU 74690	A2	19970128	HU 1996-1414	19941114
EP 970950	A2	20000112	EP 1999-119541	19941114
EP 970950	A3	20000405		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
ES 2154326	T3	20010401	ES 1995-901915	19941114
IL 111721	A1	20000601	IL 1994-111721	19941121

ZA 9409337	A	19960524	ZA 1994-9337	19941124
CA 2222147	AA	19961205	CA 1996-2222147	19960530
WO 9638426	A1	19961205	WO 1996-US7692	19960530
W: AM, AT, AU, AZ, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, HU, JP, KG, KR, KZ, LT, LU, LV, MD, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9660243	A1	19961218	AU 1996-60243	19960530
AU 723577	B2	20000831		
EP 832076	A1	19980401	EP 1996-917833	19960530
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1202893	A	19981223	CN 1996-195931	19960530
JP 11504651	T2	19990427	JP 1996-536579	19960530
BR 9609151	A	19990629	BR 1996-9151	19960530
LT 4416	B	19981228	LT 1997-182	19971124
US 6114328	A	20000905	US 1997-978295	19971125
LV 12046	B	19980920	LV 1997-239	19971229
PRIORITY APPLN. INFO.:			US 1993-157598	B2 19931124
			US 1994-232961	B2 19940422
			US 1994-337920	B2 19941110
			US 1994-337929	A2 19941110
			EP 1995-901915	A3 19941114
			US 1995-455436	A 19950531
			WO 1996-US7692	W 19960530
OTHER SOURCE(S):		MARPAT 130:66484		
GI				



AB The invention relates to novel isoxazolines and isoxazoles which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex or the vitronectin receptor. The invention also relates to pharmaceutical compns. contg. the compds., processes for prepg. the compds., and to methods of using these compds., alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of **thromboembolic** disorders. Such disorders include restenosis, atherosclerosis, stroke, myocardial infarction, and unstable angina. In particular, title compds. I are claimed [wherein: R1 = a variety of cyclic and/or acyclic N-contg. groups; R2 = H, alk(en/yn)yl, alkoxy, aryl, heteroaryl, CO2H or certain derivs.; R3 = H, OH, alky(en/yn)yl, alkoxy, alkoxycarbonyl, (un)substituted aryl or heterocyclyl, etc.; U = single bond,

alk(en/yn)ylene; V = single bond, (un)substituted alk(en/yn)ylene, C₆H₄, pyridinediyl, pyridazinediyl; W = (un)substituted (CH₂)_nCONH or CONH(CH₂)_n; X = (un)substituted alkylene; Y = OH and derivs.]. For instance, 4-hydroxybenzaldehyde was etherified with 2-[N-(tert-butoxycarbonyl)piperidin-4-yl]ethanol by Mitsunobu reaction (70%), followed by oximation of the aldehyde with NH₂OH (87%), chlorination of the oxime to give an oximinoyl chloride (52%), dipolar cycloaddn. of this with Me 3-butenate (77%), sapon. of the Me ester (74%), and hydrolysis of the BOC group with CF₃CO₂H (TFA), to give title compd. II.TFA in 60% yield. II inhibited aggregation of human platelets in vitro, using a variety of agonists, with IC₅₀ of < 10 .mu.M.

REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:479515 CAPLUS

DOCUMENT NUMBER: 129:95486

TITLE: Preparation of amidinophenyl(is)oxazolecarboxamides and analogs as factor Xa inhibitors

INVENTOR(S): Pruitt, James Russell; Fevig, John Matthew; Quan, Mimi Lifen; Pinto, Donald Joseph Phillip

PATENT ASSIGNEE(S): The Du Pont Merck Pharmaceutical Co., USA

SOURCE: PCT Int. Appl., 248 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9828282	A2	19980702	WO 1997-US23470	19971218
W: AM, AU, AZ, BR, BY, CA, CN, CZ, EE, HU, IL, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9866459	A1	19980717	AU 1998-66459	19971218
EP 946528	A2	19991006	EP 1997-954988	19971218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2001506271	T2	20010515	JP 1998-528962	19971218
PRIORITY APPLN. INFO.:				
			US 1996-771814	A 19961223
			US 1997-879763	A 19970620
			WO 1997-US23470	W 19971218

OTHER SOURCE(S): MARPAT 129:95486

GI



I

AB DEG(CH₂)_nZ1ZAB [I; A = (un)substituted carbo- or heterocyclylene; B = amino(alkyl), (un)substituted amidino(amino), carbo- or heterocyclyl, etc.; D = cyano, amino(alkyl), (un)substituted amidino(amino), etc.; E = phenylene, pyridinediyl, pyrimidinediyl, etc.; G = bond, NHCH₂, OCH₂, SCH₂; Z = alkylene, CH₂O, CO, CONH, etc.; Z1 = (un)substituted furandiyl,

-thiophenediyl, oxazolediyl, etc.; $n = 0-2$] were prepd. Thus, 3-(NC)C₆H₄C(:NOH)Cl was cyclocondensed with MeOCH:CHCO₂Me and the sapond. product amidated by 4-(H₂N)C₆H₄C₆H₄(SO₂NHMe₃)-2 (prepn. given) to give, after acid hydrolysis, title compd. II. Data for biol. activity of I were given.

L7 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:126233 CAPLUS

DOCUMENT NUMBER: 128:192644

TITLE: Preparation of amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines as inhibitors of factor Xa

INVENTOR(S): Fevig, John Matthew; Quan, Mimi Lifan

PATENT ASSIGNEE(S): Du Pont Merck Pharmaceutical Company, USA

SOURCE: PCT Int. Appl., 206 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9806694	A1	19980219	WO 1997-US14222	19970813
W: AM, AU, AZ, BR, BY, CA, CN, CZ, EE, HU, IL, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6057342	A	20000502	US 1997-888718	19970707
AU 9740645	A1	19980306	AU 1997-40645	19970813
EP 934265	A1	19990811	EP 1997-938270	19970813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2000516234	T2	20001205	JP 1998-509980	19970813
PRIORITY APPLN. INFO.:				
			US 1996-689945	A 19960816
			US 1996-33436P	P 19961223
			US 1996-23417P	P 19960816
			WO 1997-US14222	W 19970813

OTHER SOURCE(S): MARPAT 128:192644

GI



I



II

AB The title compds. [I; D, D₁ = CN, C(:NR₇)NR₈R₉, NHC(:NR₇)NR₈R₉, etc.; Z = CH₂, C(O), CH₂C(O), etc.; J₁, J₂ = O, CH₂ (provided that if J₁ = O, then J₂ = CH₂ and if J₂ = O, then J₁ = CH₂); R = CO₂R₁, COR₁, etc.; R_a = H, C₁-4 alkyl; R_b = H; when J₁, J₂ = CH₂, then R_a, R_b = a bond; R₁ = H, (un)substituted C₁-4 alkyl, C₃-6 carbocyclyl, etc.; A = (un)substituted

C3-13 carbocyclyl, 5-10 membered heterocyclyl; B = XY, NR₂R₂a, C(:NR₂)NR₂R₂a, etc.; X = C1-4 alkylene, C(O), C(O)NR₂, etc.; Y = (un)substituted C3-10 carbocyclyl, 5-10 membered heterocyclyl; R₂, R₂a = H, C1-4 alkyl, Ph; R₂R₂a = (un)substituted 5-6 membered ring; R₇ = H, OH, C1-6 alkyl, etc.; R₈, R₉ = H, C1-6 alkyl, (CH₂)_nphenyl; n = 0-3; m = 0-2] and their salts, useful as anticoagulants in treating or preventing thromboembolic disorders, were prepd. Thus, treatment of 3-cyanobenzaldehyde with Me (triphenylphosphoranylidene)acetate followed by reacting the resulting Me trans-3-cyanocinnamate with N-benzyl-N-(trimethylsilylmethyl)aminomethyl Me ether, and HCl gas bubbling through the soln. of trans-1-benzyl-3-carbomethoxy-4-(3-cyanophenyl)pyrrolidine, and treatment of the resulting solid with (NH₄)₂CO₃ in MeOH afforded the title compd. trans-II. Some compds. I were evaluated and showed K_i of < 5 .mu.M against human thrombin.

L7 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:503386 CAPLUS

DOCUMENT NUMBER: 127:135788

TITLE: Preparation of isoxazoline, isothiazoline and pyrazoline as factor Xa inhibitors

INVENTOR(S): Quan, Mimi Lifen; Wityak, John; Galemno, Robert Anthony, Jr.; Stouten, Petrus F. W.; Pruitt, James Russell

PATENT ASSIGNEE(S): Du Pont Merck Pharmaceutical Company, USA

SOURCE: PCT Int. Appl., 191 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9723212	A1	19970703	WO 1996-US20076	19961217
W: AM, AU, AZ, BR, BY, CA, CN, CZ, EE, HU, IL, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2240946	AA	19970703	CA 1996-2240946	19961217
AU 9713358	A1	19970717	AU 1997-13358	19961217
EP 874629	A1	19981104	EP 1996-944844	19961217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
US 5939418	A	19990817	US 1996-768908	19961217
JP 2001502655	T2	20010227	JP 1997-523762	19961217
PRIORITY APPLN. INFO.:			US 1995-9508P	P 19951221
			US 1996-646903	A 19960508
			US 1996-30666P	P 19961112
			WO 1996-US20076	W 19961217

OTHER SOURCE(S): MARPAT 127:135788

GI



AB The title compds. [I; U = CONH(CH₂)_o, CO(CH₂)_o, SO₂NH(CH₂)_o, etc.; o = 0-2; X = O, S, etc.; Y = (un)substituted aryl or heteroaryl, etc.; R₁ = (CH₂)_pNR₅R₆, CONR₅R₆, etc.; R₅, R₆ = H, C1-6 alkyl, etc.; R₂ = H, C1-6 alkyl or alkoxy, COR₅, etc.; U, R₂ = may combine together to provide a spiro compd. of heterocycle; V = (un)substituted aryl or heteroaryl, etc.; Z = CO, single bond, NH, O, etc.; D = (un)substituted aryl or heteroaryl, etc.; u = 0-1; m = 0-2; n = 0-4] are prepd. I, possessing Factor Xa inhibitory activity, are useful as anticoagulant agents for treatment and prevention of **thromboembolic** disorders (no data). Thus, isoxazoline deriv. (II; X = CN) (prepn. given) was treated with HCl gas and then reacted with NH₄OAc. The reaction mixt. was purified by HPLC eluted with F₃CCO₂H (TFA) to give 20% the title compd. II.3TFA (X = NH₂C:NH).

L7 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:105201 CAPLUS

DOCUMENT NUMBER: 126:117965

TITLE: Preparation of novel isoxazoline and isoxazole fibrinogen receptor antagonists

INVENTOR(S): Wityak, John; Cain, Gary Avonn; Batt, Douglas Guy; Pinto, Donald; Hussain, Munir Alwan; Xue, Chu-Biao; Sielecki-Dzurdz, Thais Motria; Olson, Richard Eric; Degrado, William Frank; Mousa, Shaker Ahmed

PATENT ASSIGNEE(S): Du Pont Merck Pharmaceutical Company, USA

SOURCE: PCT Int. Appl., 412 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9638426	A1	19961205	WO 1996-US7692	19960530
W: AM, AT, AU, AZ, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, HU, JP, KG, KR, KZ, LT, LU, LV, MD, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

US 5849736	A	19981215	US 1995-455436	19950531
AU 9660243	A1	19961218	AU 1996-60243	19960530
AU 723577	B2	20000831		
EP 832076	A1	19980401	EP 1996-917833	19960530




R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

JP 11504651	T2	19990427	JP 1996-536579	19960530
BR 9609151	A	19990629	BR 1996-9151	19960530

PRIORITY APPLN. INFO.:

US 1995-455436	A	19950531
US 1993-157598	B2	19931124
US 1994-232961	B2	19940422
US 1994-337920	B2	19941110
WO 1996-US7692	W	19960530

OTHER SOURCE(S): MARPAT 126:117965
GI



AB The title compds. [I; R1 = R2NR3(CH2)qZ- (wherein R2, R3 = H, C1-10 alkyl, C2-6 alkenyl, etc.; Z O, S, SO, SO2, etc.; q = 2-7), piperazinyl(CH2)qZ-, etc.; U = a single bond, C1-7 alkyl, C2-7 alkenyl, etc.; V = a single bond, (un)substituted C1-7 alkyl, etc.; W = a single bond, C1-7 alkyl, C2-7 alkenyl, etc.; X = a single bond, (un)substituted C1-7 alkyl, etc.; Y = OH, C1-10 alkoxy, etc.; R4 = H, C1-10 alkyl, C2-10 alkenyl, etc.; R5 = H, (un)substituted C1-10 alkyl, C2-10 alkenyl, etc.], useful alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of **thromboembolic** disorders selected from, e.g. restenosis, atherosclerosis, stroke, myocardial infarction, and unstable angina, were prepd. and formulated. Thus, reaction of Me 3-(3-butenoyl)amino-3-phenylpropionate with 4-cyanobenzaldoxime in CH2Cl2 in the presence of 5% NaOCl (aq.) followed by treatment of the intermediate II in 10% DCM/MeOH with gaseous HCl, addn. of (NH4)2CO3 to the crude imidate in MeOH, and sapon. afforded III which showed IC50 of <10 .mu.M against platelet aggregation. Compds. I are useful also for treating rheumatoid arthritis, asthma, allergies, organ transplantation rejection, septic shock, psoriasis, contact dermatitis, osteoporosis, osteoarthritis, tumor metastasis, diabetic retinopathy, and inflammatory conditions.

09/ 924,381

=> d his

(FILE 'HOME' ENTERED AT 12:58:38 ON 02 MAY 2002)

FILE 'REGISTRY' ENTERED AT 12:58:42 ON 02 MAY 2002

L1 949882 S PYRAZOL? OR TRIAZOL? OR TETRAZOL? OR ISOXAZOL?
L2 17350 S (SULPHONYL OR SULFONYL) AND BIPHENYL
L3 2804 S L1 AND L2
L4 822183 S (ISOQUINOLIN? OR BENZISOXAZOL? OR INDAZOL? OR QUINOLIN? OR QU
L5 2804 S L1 AND L2 AND L3

FILE 'CAPLUS' ENTERED AT 13:03:38 ON 02 MAY 2002

L6 299 S L5
L7 12 S L6 AND THROMBOEMBOL?

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
29.89	81.14

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-7.43	-7.43

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 13:04:43 ON 02 MAY 2002